Alexium International Group (ASX:AJX) Total Liabilities : A$12.71 Mil (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Alexium International Group Total Liabilities?

Alexium International Group's Total Liabilities for the quarter that ended in Dec. 2023 was A$12.71 Mil.

Alexium International Group's quarterly Total Liabilities declined from Dec. 2022 (A$10.89 Mil) to Jun. 2023 (A$9.48 Mil) but then increased from Jun. 2023 (A$9.48 Mil) to Dec. 2023 (A$12.71 Mil).

Alexium International Group's annual Total Liabilities declined from Jun. 2021 (A$8.24 Mil) to Jun. 2022 (A$6.90 Mil) but then increased from Jun. 2022 (A$6.90 Mil) to Jun. 2023 (A$9.48 Mil).

Alexium International Group Total Liabilities Historical Data

The historical data trend for Alexium International Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexium International Group Total Liabilities Chart

Alexium International Group Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

13.21

9.05

8.24

6.90

9.48

Alexium International Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															9.24	6.90	10.89	9.48	12.71

Alexium International Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alexium International Group's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.919	+	(6.538	+	1.025
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	9.48

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	8.018	-	-1.465
	=	9.48

Alexium International Group's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.989	+	(9.432	+	1.288
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	12.71

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	8.114	-	-4.596
	=	12.71

Alexium International Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Alexium International Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Alexium International Group (ASX:AJX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Alexium International Group Ltd (ASX:AJX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

E7T:Germany

Address

350 West Phillips Road, Greer, SC, USA, 29650

Website

https://www.alexiuminternational.com

Alexium International Group Ltd is engaged in the development of specialty chemicals. Its only operating segment is the development and commercialization of its proprietary flame retardant (FR) and phase change material (PCM) chemistries, cooling products for bedding, and selling its specialized chemistry to customers. Geographically, it derives a majority of its revenue from the United States and also has a presence in Australia. The company products include Alexicool and Alexiflam NF.